Abstract 1214
Background
GISTs are rare tumours with an incidence of around 1/100000/year. The principle treatment in localised disease remains resection. If an R0 resection is not expected, Imatinib can be used in the NA setting to shrink tumours and improve chances of a complete resection. Current guidelines suggest Imatinib should be used for 6-12 months in the NA setting.
Methods
Data were collected for patients treated for GISTs with Imatinib in either the NA or palliative (PA) setting in two UK tertiary centres to assess response in the primary tumour volume (PTV). This study aimed to find the time to maximum reduction of PTV in NA and PA settings.
Results
29 patients were treated with Imatinib over a 3 year period; 13 in the PA setting and 16 in the NA setting. In the NA setting, 10 patients proceeded to surgery, 2 patients declined surgery and 4 patients remained inoperable. All patients deemed operable at baseline underwent surgery after NA Imatinib. The median time to surgery was 7.2mths (Range (R) 1.6 – 28.9mths). Overall, 10 patients died (none in the NA setting), 5 on treatment and 5 post-treatment. At baseline, the median PTV was 199.3cm3 (R 4.0 – 10472.0cm3). The median time to best response was 7.6mths (R 1.4 – 46.2mths) for all patients, 4.7mths (R 1.4 – 21.6mths) in NA patients and 14.1mths (R 3.3 – 46.2mths) in PA patients. As the majority of NA patients did not have progressive disease (PD) prior to surgery, the maximum response may not have been reached and therefore the results in PA patients may better reflect the time to best response. 9 patients had PD, 2 in NA setting with 1 patient proceeding to surgery. The median time to PD for all patients was 19.6mths (R 1 – 51.4mts). The overall response rate to Imatinib was 85.2%. The median reduction in PTV was 65.3% (R -182.7 – 93.4%). In NA patients the median reduction in PTV was 62.7% (R -182.7 – 93.4%) and in PA patients the median reduction in PTV was 57.6% (R 20 – 82.4%).
Conclusions
Imatinib has high response rates in both the NA and PA settings. This study suggests the maximum reduction in PTV can be achieved after greater than 12mths of treatment. For patients responding to NA Imatinib who have ongoing concerns regarding resectability, a more prolonged course of treatment may further reduce PTV to facilitate an R0 resection.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sharath Gangadhara.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3181 - Effects of Three Products in the Prevention and Treatment of Chemotherapy and Radiation Therapy-Induced Oral Mucositis
Presenter: Francesca Zannier
Session: Poster Display session 1
Resources:
Abstract
2433 - Boiling Histotripsy-induced Mechanical Ablation Modulates Tumour Microenvironment by Promoting Immunogenic Cell Death of Cancers
Presenter: Cheol-Hee Shin
Session: Poster Display session 1
Resources:
Abstract
2663 - The bacterial receptor NOD2 mediates LGR5+ intestinal stem cells protection against irradiation via mitophagy activation
Presenter: Antonin Levy
Session: Poster Display session 1
Resources:
Abstract
3213 - Pulse mode irradiation regimen of PDT results in high progression free and overall survival in mice with model tumor
Presenter: Alexey Bogdanov
Session: Poster Display session 1
Resources:
Abstract
3722 - Proton-sensitizing effect of small molecule inhibitor of P300 histone acetyltransferase C646 in human pancreatic cancer cells.
Presenter: Sungwon Shin
Session: Poster Display session 1
Resources:
Abstract
5805 - Red-Blood-Cell-Membrane-Enveloped Magnetic Nanoclusters as a Biomimetic Theranostic Nanoplatform for Bimodal Imaging Guided Cancer Photothermal Therapy
Presenter: sheng wang
Session: Poster Display session 1
Resources:
Abstract
5251 - Urine cell-free and extracellular vesicle cargo miRNAs as biomarkers for prostate cancer diagnosis
Presenter: Ivan Zaporozhchenko
Session: Poster Display session 1
Resources:
Abstract
3657 - Parkin, APEX1 and BCL2L1 Tissue Expression in Southern Brazilian Patients with Different Breast Cancer Molecular Subtypes
Presenter: Bianca Cabral
Session: Poster Display session 1
Resources:
Abstract
2839 - Obesity and prognosis in breast cancer
Presenter: Noha Ibrahim
Session: Poster Display session 1
Resources:
Abstract
5132 - SIPA1 is a modulator of HGF induced tumor metastasis via the regulation of tight junctions in lung adenocarcinoma cells
Presenter: Chang Liu
Session: Poster Display session 1
Resources:
Abstract